Premium
O1‐12‐05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O‐GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES
Author(s) -
Ryan J. Michael,
Quattropani Anna,
Abd-Elaziz Khalid,
Daas Izaak,
Schneider Manfred,
Ousson Solenne,
Neny Maud,
Sand Astrid,
Hantson Jennifer,
Permanne Bruno,
Wiessner Christoph,
Beher Dirk
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2400
Subject(s) - tolerability , medicine , progressive supranuclear palsy , pharmacokinetics , placebo , tauopathy , adverse effect , pharmacology , neurodegeneration , anesthesia , disease , pathology , alternative medicine
O1-12-05 PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O-GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSYAND RELATED TAUOPATHIES J.Michael Ryan, AnnaQuattropani, Khalid Abd-Elaziz, Izaak den Daas, Manfred Schneider, Solenne Ousson, Maud Neny, Astrid Sand, Jennifer Hantson, Bruno Permanne, Christoph Wiessner, Dirk Beher, Asceneuron SA, Lausanne, Switzerland; Asceneuron SA, Lausanne, Switzerland; QPS Netherlands BV, Groningen, Netherlands. Contact e-mail: dirk.beher@asceneuron.com